For treatment-naïve and virologically suppressed adults with HIV-1. See Full Indication.

EDUCATIONAL RESOURCES

FOR DOVATO

EDUCATIONAL RESOURCES

FOR DOVATO

See the full Prescribing Information, including Boxed Warning, for DOVATO, an innovative approach with DTG at the core for treatment-naïve and virologically suppressed adult patients with HIV-1

DHHS guidelines include updated recommendations

Hear from a patient living with HIV-1 and learn more about DOVATO

Take a deeper dive into GEMINI data in this video with Dr. Lisa Capaldini, a paid consultant/speaker for ViiV Healthcare.

Hear Dr. Benjamin Young, Head of Global Medical Directors for ViiV Healthcare, review 96-week data for DOVATO

DOVATO inhibits the viral life cycle at 2 separate sites like a traditional 3-drug regimen

“I may be HIV positive… but my diagnosis does not define me.”

Answer questions to test your familiarity with DOVATO. Upon completion, you’ll have a greater working knowledge of DOVATO

DHHS=Department of Health and Human Services; DTG=dolutegravir.

DLLWCNT200029

ARROW

IMPORTANT SAFETY INFORMATION

BOXED WARNING: PATIENTS CO-INFECTED WITH HEPATITIS B VIRUS (HBV) AND HIV-1: EMERGENCE OF LAMIVUDINE-RESISTANT HBV AND EXACERBATIONS OF HBV

All patients with HIV-1 should be tested for the presence of HBV prior to or when initiating DOVATO. Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported. If DOVATO is used in patients co-infected with HIV-1 and HBV, additional treatment should be considered for appropriate treatment of chronic HBV; otherwise, consider an alternative regimen.

Severe acute exacerbations of HBV have been reported in patients who are co-infected with HIV-1 and HBV and have discontinued lamivudine, a component of DOVATO. Closely monitor hepatic function in these patients and, if appropriate, initiate anti-HBV treatment.

Contraindications

Do not use DOVATO in patients with previous hypersensitivity reaction to dolutegravir or lamivudine

Do not use DOVATO in patients receiving dofetilide

Warnings and precautions

Hypersensitivity Reactions:

Hypersensitivity reactions have been reported with dolutegravir and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury

Discontinue DOVATO immediately if signs or symptoms of severe skin or hypersensitivity reactions develop, as a delay in stopping treatment may result in a life-threatening reaction. Clinical status, including liver aminotransferases, should be monitored and appropriate therapy initiated

Hepatotoxicity:

Hepatic adverse events have been reported, including cases of hepatic toxicity (elevated serum liver biochemistries, hepatitis, and acute liver failure), in patients receiving a dolutegravir-containing regimen without pre-existing hepatic disease or other identifiable risk factors

Patients with underlying hepatitis B or C or marked elevations in transaminases prior to treatment may be at increased risk for worsening or development of transaminase elevations with use of DOVATO. In some cases, the elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation, particularly in the setting where anti-hepatitis therapy was withdrawn

Monitoring for hepatotoxicity is recommended

Embryo Fetal Toxicity:

Alternative treatments to DOVATO should be considered at the time of conception through the first trimester of pregnancy due to the risk of neural tube defects

Perform pregnancy testing before use of DOVATO and counsel that consistent use of effective contraception is recommended while using DOVATO in individuals of childbearing potential

Lactic Acidosis and Severe Hepatomegaly with Steatosis:

Fatal cases have been reported with the use of nucleoside analogs, including lamivudine. Discontinue DOVATO if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations.

Adverse Reactions or Loss of Virologic Response Due to Drug Interactions with concomitant use of DOVATO and other drugs may occur (see Contraindications and Drug interactions).

Immune Reconstitution Syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported with the use of DOVATO.

Adverse reactions

The most common adverse reactions (incidence ≥2%, all grades) with DOVATO were headache (3%), nausea (2%), diarrhea (2%), insomnia (2%), fatigue (2%), and anxiety (2%).

Drug interactions

Consult full Prescribing Information for DOVATO for more information on potentially significant drug interactions

DOVATO is a complete regimen. Coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended

Drugs that induce or inhibit CYP3A or UGT1A1 may affect the plasma concentrations of dolutegravir

Administer DOVATO 2 hours before or 6 hours after taking polyvalent cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, DOVATO and supplements containing calcium or iron can be taken with food

Use in specific populations

Pregnancy: There are insufficient human data on the use of DOVATO during pregnancy to definitively assess a drug-associated risk for birth defects and miscarriage. An Antiretroviral Pregnancy Registry has been established. If planning a pregnancy or if pregnancy is confirmed while taking DOVATO during the first trimester, assess the risks and benefits of continuing DOVATO versus switching to another antiretroviral regimen. For individuals actively trying to become pregnant, initiation of DOVATO is not recommended unless there is no suitable alternative

Lactation: Breastfeeding is not recommended due to the potential for HIV-1 transmission, developing viral resistance in HIV-positive infants, and adverse reactions in a breastfed infant

Females and Males of Reproductive Potential: Perform pregnancy testing before initiation of DOVATO. Advise individuals of childbearing potential to consistently use effective contraception while taking DOVATO

Renal Impairment: DOVATO is not recommended for patients with creatinine clearance <50 mL/min

Hepatic Impairment: DOVATO is not recommended in patients with severe hepatic impairment (Child-Pugh Score C)

INDICATION

DOVATO is indicated as a complete regimen to treat HIV-1 infection in adults with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of DOVATO.

Please see full Prescribing Information, including Boxed Warning, for DOVATO.

DLLWCNT200023

To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at
1-877-844-8872 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.

Comprehensive patient support
programs and resources
for healthcare providers

Benefits
Verification

Prior Authorization
and Appeals Support

Financial Assistance
Programs*

Call to speak to an Access Coordinator

1-844-588-3288 (toll-free)

Monday-Friday,

8AM-11PM (ET)

Get support from ViiVConnnect

LEARN MORE

*Subject to eligibility and program terms and conditions;
ViiVConnect programs do not constitute health insurance.

Comprehensive information on access & coverage to help patients get their prescribed ViiV Healthcare medications Insured • Underinsured • Uninsured

LEARN MORE

1-844-588-3288 (toll free)
Monday-Friday, 8AM-11PM (ET)

www.viivconnect.com

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

This site is funded and developed by ViiV Healthcare.

The other brands listed are trademarks of their respective owners and are not trademarks of the ViiV Healthcare group of companies.

The makers of these brands are not affiliated with and do not endorse the ViiV Healthcare group of companies or its products.

This site is intended for US healthcare professionals only.

Trademarks are owned by or licensed to the

ViiV Healthcare group of companies.

This site is funded and developed by

ViiV Healthcare.

The other brands listed are trademarks of their respective owners and are not trademarks of the ViiV Healthcare group of companies.

The makers of these brands are not affiliated with and do not endorse the ViiV Healthcare group of companies or its products.

This site is intended for US healthcare

professionals only.

November 2020 Produced in USA.

By completing this registration, you are giving ViiV Healthcare, and companies working with ViiV Healthcare, permission to market or advertise to you across multiple channels, e.g, mail, websites, email, online advertising, applications, and services, regarding professional information from ViiV Healthcare. ViiV Healthcare will not sell or share this information with third parties for their marketing purposes and will always provide you with the opportunity to change your advertising preferences.

EDUCATIONAL RESOURCES

FOR DOVATO

EDUCATIONAL RESOURCES

FOR DOVATO

Prescribing Information

Updated Guidelines

Hear From a Patient

Peer Perspective

96-Week Data Video

Mechanism of Action Video

Power Reimagined Video

Interactive Quiz